Santero Therapeutics SRL
11.9 FTESantero Therapeutics reported total assets of €4.15m at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Jul 2026), with 11.9 full-time equivalents.
By total assets for 2025, Santero Therapeutics ranks among the 200 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Santero Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +580 % Total assets +515 % Headcount (avg FTE) +358 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Santero Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Jul 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 19 Jun 2024
- Year ended 31 Dec 2022filed on 20 Jun 2023
- Year ended 31 Dec 2021filed on 13 Jun 2022
Santero Therapeutics's financial analysis
- Solvency87.5%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Santero Therapeutics
11 active director(s) in the register.
and 5 more
Santero Therapeutics's shareholders and holdings →Santero Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0765.790.155
- VAT number
- BE0765790155
- Peppol
- Registered · 0208:0765790155 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Mar 2021
- Registered office
- 6041 Charleroi
- Size
- Small · 11.9 FTE
- Latest accounts
- 2025 · filed on 24 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Santero Therapeutics (SRL) has been based in Charleroi since 2021, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €2.15m and equity of €3.63m; its revenue is not published. With 11.9 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 87.5%, above the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Santero Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- Cancer State Therapeutics Research and experimental development on natural sciences and engineering Charleroi · balance sheet €3.96m
- Zymofix Research and experimental development on natural sciences and engineering Ghent · balance sheet €2.41m
- Nexelis Europe Research and experimental development on natural sciences and engineering Charleroi · balance sheet €4.65m
- BiometrIQ Research and experimental development on natural sciences and engineering Kortrijk · balance sheet €1.65m
- Protealis Research and experimental development on natural sciences and engineering Ghent · balance sheet €11.1m
- Biotalys Research and experimental development on natural sciences and engineering Ghent · balance sheet €16.3m
- Nanocyl Research and experimental development on natural sciences and engineering Sambreville · balance sheet €13.2m
- Dendrogenix Research and experimental development on natural sciences and engineering Liège · balance sheet €5.28m
Frequently asked questions about Santero Therapeutics
What is the revenue of Santero Therapeutics?
Santero Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Santero Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0765790155 for Santero Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0765.790.155.
Where is the registered office of Santero Therapeutics?
According to the CBE register, the registered office of Santero Therapeutics is in 6041 Charleroi.
What is the equity of Santero Therapeutics?
At the close of the 2025 financial year, the equity of Santero Therapeutics amounts to 3,631,776 €, a solvency of 87.5% of total assets.
How many people work at Santero Therapeutics?
11.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Santero Therapeutics?
The register lists 11 active mandates at Santero Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Santero Therapeutics within its sector?
By total assets for 2025, Santero Therapeutics ranks among the 200 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of Santero Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →